Our sequencing pipeline was able to detect the most prominent CNVs, such as the amplifications of MYC (22.2% of cases) and HER2 (22.2%), from the tumor DNA sequencing data, although the used gene panel was not specifically designed to identify CNVs from sequenced samples. Here, ERBB2 is linked to neoplasm.